Screening Strategies in Drug Discovery – News and Features

Learn how AI and machine learning enhance antibody discovery – from structure prediction to binding optimization – with robust data and lab informatics.

Discover how Agilent's AssayMAP Bravo and RapidFire systems accelerate drug discovery with automation and rapid, reliable mass spectrometry.

Scientists have discovered novel drug candidates that could ultimately lead to new effective treatments for conditions caused by tissue stress and inflammation, including neuropathic pain and ischemia-reperfusion injury.

From theory to clinic, explore how molecular glue innovation is transforming targeted protein degradation for cancer and other diseases. Offering a new path to degrade targets once thought undruggable.

Structure verification by NMR is a vital task in drug discovery but can be slow and subjective. This article explores how ASV transforms it into a scalable, consistent and reliable process.

To be able to study ALS-linked neuroinflammation in the lab, researchers generated “spinal microtissues” containing motor neurons and immune cells from ALS patients' stem cells.

This article explores how AI is transforming precision medicine by streamlining drug discovery, improving patient stratification and treatment prediction, and accelerating clinical trials while highlighting challenges around data quality.

This article explores how generative chemistry accelerates drug design, identifies novel compounds and complements traditional computational tools.

Researchers have identified several uncharacterized chromatin factors and a gene that are involved in DNA repair.

Researchers have identified a small molecule that can selectively block cell death. The findings lay the groundwork for next-generation neuroprotective drugs for degenerative conditions, which currently have no cure or treatments.